Mitiglinide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mitiglinide
Mitiglinide.svg
Clinical data
Trade namesGlufast
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth (tablets)
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H25NO3
Molar mass315.41 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology[edit]

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Dosage[edit]

Mitiglinide is delivered in tablet form.

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
  2. ^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. Archived from the original on 2015-09-24. Cite uses deprecated parameter |deadurl= (help)

External links[edit]